For over 60 years, chronic oral anticoagulation with vitamin K antagonists has been the stan dard therapy for patients with venous thrombo embolism, and it is used in the prevention of systemic embolism in patients with atrial fibrilla tion and prosthetic heart valves [1,2]. Warfarin is the most commonly prescribed vitamin K antag onists worldwide and is administered to more than 1 million patients in the USA annually [3].
For over 60 years, chronic oral anticoagulation with vitamin K antagonists has been the stan dard therapy for patients with venous thrombo embolism, and it is used in the prevention of systemic embolism in patients with atrial fibrilla tion and prosthetic heart valves [1, 2] . Warfarin is the most commonly prescribed vitamin K antag onists worldwide and is administered to more than 1 million patients in the USA annually [3] .
Chronic anticoagulation with warfarin is limited by its narrow therapeutic range, risk of bleeding, numerous drug and dietary inter actions and the inconvenience of regular inter national normalized ratio (INR) monitoring. These problems result in discontinuation of warfarin therapy in many patients who are at high risk of thromboembolism.
Major bleeding is an important concern with anticoagulation therapy, and warfarin is one of the leading causes of attendance to the emer gency department and hospitalization owing to adverse drug events [4] . Analysis of 3791 warfa rintreated patients from the National Registry of Atrial Fibrillation revealed that the rate of admissions for bleeding was 5.2 per 100 patient years. Of these, 67.3% were gastrointestinal and 15.4% were intracranial hemorrhage; the over all 30day mortality of patients admitted with major hemorrhage was 21.6% [5] .
Many factors associated with increased risk of bleeding among individuals taking warfarin have been identified. These risk factors have been summarized into a bleeding classification scheme to predict the probability of major bleeding, known as the hepatic or renal dis ease, ethanol use, malignancy, older age (>75 years), reduced platelet count or func tion, rebleeding, hypertension, uncontrolled anemia, genetic factors, elevated risk of fall and stroke (HEMORR 2 HAGES) index. A score can be obtained by adding 2 points for a prior bleed and 1 point for each of the other risk factors previously listed. The risk of bleeding increases with each additional point (Table 1 ) [5] .
Recently, variations in two genes, the vita min K epoxide reductase (VKOR) complex 1 (VKORC1) and cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9) have been associated with longer times to warfarin dose stabilization, and CYP2C9 has been associated with a higher risk of serious and lifethreatening bleeding. Recent studies suggest that routine use of genetic testing in warfarin therapy may be a lifesaving strategy in preventing serious bleeding and stroke. In August 2007, the US FDA updated the label for warfarin to highlight genetic testing to predict warfarin response, and subsequently approved the first commercial genetic test for variations in these two genes. . We aim to review the pharmaco genetics of warfarin metabolism and the clinical role of genetic testing in warfarin therapy.
Search method & strategy
References for this review were identified through searches of MEDLINE, EMBASE and Cochrane Library with the search terms Chronic oral anticoagulation with warfarin is difficult to maintain within the therapeutic range and requires frequent monitoring and dose adjustments. Variations in two genes, VKORC1 and CYP2C9, have been associated with variation in warfarin metabolism among individuals. Patients with CYP2C9*2 and *3 variants have longer times to dose stabilization and are at higher risk of serious and life-threatening bleeding. VKORC1 polymorphisms significantly influence time to first therapeutic warfarin range, and variants in this gene determine low-, intermediate-and high-warfarin dose requirements. The prevalence of CYP2C9 and VKORC1 polymorphisms vary among different ethnic groups, and can account for over 30% of variance in warfarin dose. Recent studies suggest that the pharmacogenomics-guided dosing algorithm can accurately predict warfarin dosage and might reduce adverse events. We aim to review the pharmacogenetics of warfarin metabolism and the clinical role of genetic testing for warfarin therapy.
'anticoagulation therapy OR warfarin OR oral anticoagulants' AND 'polymorphism', 'pharmacogenetics', 'CYP2C9', 'VKORC1', 'cost-effectiveness'. The search included papers that were published up until December 2009. Only papers published in English were reviewed.
Pharmacology of warfarin
Warfarin is a watersoluble, strongly protein bound drug with high bioavailability and a biological halflife of 36-42 h. It is manufac tured as a mixture of R and Senantiomers, with the more potent Sform of the drug being metabolized primarily by the CYP2C9 enzyme of the cytochrome P450 system [1, 6] .
Clotting factors II, VII, IX and X are synthe sized in the liver as inactive proteins and require reduced vitamin K as a cofactor for the ggluta myl carboxylation they require to become func tional. Reduced vitamin K is regenerated by VKOR by converting oxidized vitamin K to its reduced form (Figure 1) [1] . The anticoagulant effect of warfarin is mediated through inhibi tion of VKOR enzyme complex, specifically the VKORC1 subunit [7] , resulting in hepatic synthesis of partially carboxylated or decarbox ylated proteins with reduced coagulant activity. Warfarin also inhibits carboxylation of regula tory anticoagulant proteins C and S, which has the potential to cause thrombogenic risk dur ing initial administration. Peak anticoagulant effect occurs 36-72 h after drug administration when clotting factors, especially prothrombin, are cleared from the circulation [8] .
Monitoring of warfarin therapy
Warfarin has a narrow therapeutic range and over or underdosing of warfarin can lead to catastrophic hemorrhagic or thrombotic 
Pharmacogenomics of warfarin
More than 30 genes have been discovered so far that are involved in warfarin metabolism and action. The CYP2C9 gene is one of the most important genes in the pharmacokinetics of war farin, and the VKORC1 gene also plays a key role in pharmacodynamics of warfarin [14] . n CYP2C9 CYP2C9 is the key enzyme in metabolism of the more potent Swarfarin. Since 1999, genetic polymorphisms in CYP2C9 have been studied as a cause of interindividual variation of warfa rin response [11, 15] . The CYP2C9 gene is located on chromosome 10q:24.2, is approximately 55kb long and contains 9 exons and encodes for a 60kDa microsomal protein [16, 17] . The fre quency of the most common allele, designated CYP2C9*1, varies from 81 to 96% in different ethnic groups, and is considered the wildtype genotype. A total of 13 polymorphisms of the CYP2C9 gene have been identified. The com monest, CYP2C9*2 (C430T, rs1799852) and CYP2C9*3 (A1075C, rs1057910), occur at a fre quency of 6-13% and 1-9%, respectively [13, 18] . A metaana lysis of 7907 subjects found that 72.7% were wildtype homozygous, 15.4% were CYP2C9*1/*2, 9.6% were CYP2C9*1/*3, 1% were CYP2C9*2/*2, 1% were CYP2C9*2/*3 and 0.3% were CYP2C9*3/*3 [14] .
The maximum rate of metabolism (V max ) of CYP2C9*2 (Arg144Cys) is 50% less than that of the wildtype, resulting in a 30-50% lower turn over of Swarfarin. CYP2C9*3 (Ile359Leu) has markedly higher K m and lower intrinsic clear ance, leading to approximately 90% decrease in Swarfarin 7hydroxylation [9] . Possession of either of these genes, therefore, is associated with slower metabolism of warfarin and higher susceptibility to warfarin overdose.
In a prospective study of patients commencing on warfarin therapy, Schwarz et al. found that the CYP2C9 genotype was a significant predic tor of time to the first INR being greater than four days and a significant predictor of the aver age dose of warfarin required after 28 days to achieve therapeutic INR, after adjustment for variables such as age, race, sex and use of amio darone. The dose was highest in those with *1/*1 genotype (5.18 mg/day), intermediate in those with the *1/*2 or *1/*3 genotype (4.25 mg/day) and lowest in those with the *2/*2, *3/*3 or *2/*3 genotypes (3.36 mg/day) [12] .
In another retrospective study evaluating the association between variant CYP2C9 alleles and clinical outcomes, it was found that dur ing warfarin initiation, patients who had at least one variant allele, compared with those with the wildtype genotype, required a lower main tenance dose, as well as a significantly longer time (median difference of 95 days) to reach a stable dose. These patients were also more likely to be overanticoagulated (INR > 4.0) and had a higher risk of a serious or life threatening bleeding event (hazard ratio: 2.39; 95% CI: 1.18-4.86) [11] .
The CYP2C9*3 variant, in particular, was found to be strongly associated with supratherapeutic anticoagulation in the Warfarin Genetics study [19] . In this study of 1496 patients, homozygosity for *3 substan tially increased the risk of overanticoagulation (HR: 21.84; 95% CI: 9.46-50.42) during the first 5 weeks of treatment. Moreover, 12.5% of CYP2C9*3/*3 patients experienced severe bleed ing during the first month compared with 0.27% of patients with other genotypes (p = 0.07).
The influence of CYP2C9 polymorphism on warfarin dose requirements was evaluated in a recent metaana lysis of 39 studies. Warfarin dose reductions associated with the five most common variant CYP2C9 genotypes were cal culated, and it was reported that, compared with the CYP2C9*1/*1 genotype, patients with *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3 required warfarin doses that were 19.6% (95% CI: 17.4-21.9), 33.7% (29. Role of warfarin pharmacogenetic testing in clinical practice Review n VKORC1 As mentioned earlier, VKOR is the target enzyme for warfarin to exert its anti coagulation effect. This enzyme is inhibited by warfarin to regenerate the reduced vitamin K from its epoxide form. Reduced vitamin K is an essential cofactor for gglutamyl carboxylase (GGCX), the enzyme catalyzing the posttranslational carboxylation of vitamin Kdependent clotting factors II, VII, IX and X, resulting in reduced coagulation [25] .
The enzyme VKOR was first identified in 1974 [26] Five common haplotypes (H1, H2, H7, H8 and H9) were identified as having more than 5% frequency in the European-American popula tion, and these haplotypes were grouped into two according to their association with warfarin dose requirement (Table 2) . Group A, comprising H1 and H2, is associated with low warfarin dos age, and group B, comprising H7, H8 and H9, is associated with high dosage, respectively. The haplotypes group A/A requires 2.7 ± 0.2 mg of warfarin per day, group A/B 4.9 ± 0.2 mg per day and B/B 6.2 ± 0.3 mg per day [27, 28] . This relationship was confirmed by Schwarz et al. in their study to determine the influence of genetic variant during the initiation of anticoagulation therapy [12] . In this study, the authors also dem onstrated that patients with group A haplotype were more sensitive to warfarin in that the thera peutic range of INR, as well as first outofrange INR, were reached in a shorter period of time. n CYP4F2 & other genetic factors In addition to VKORC1 and CYP2C9, there are several other genes that may influence varia tion in warfarin metabolism. The DNA variant (rs2108622; V433M) in CYP4F2 was recently demonstrated to be associated with warfarin dose variation in a cohort study [29] , where patients with TT alleles required approximately 1 mg/day more warfarin than patients with CC alleles. This correlation was confirmed by Borgiani et al. using multiple linear regression analyses [30] .
With the completion of the Human Genome Project, geneticists have recently begun assaying genetic markers covering the entire genome to systematically search for genes that cause disease. This genomewide association study (GWAS) has been extended to identify genes that alter response to warfarin. 10 ) at CYP4P2 was also detected, which accounted for approximately 1.5% of dose variance [31] .
Other genes that might have influential effects on warfarin, include those coding for clotting factors (such as factors II, VII, IX and X), as well as apolipoprotein E (ApoE), calumenin, microsomal epoxide hydrolase (mEH) and mul tidrug resistance 1 (ABCB1), have been studied but have not been consistently demonstrated to have a significant association with warfarin dose requirements [4] .
Interethnic genetic variation
Ethnicity is an important factor influencing warfarin dosage requirement. Chinese patients are known to be more sensitive to warfarin and require 40-50% lower maintenance dose of warfarin when compared with Europeans [32] , while the African-American population requires a higher maintenance dose. These dif ferences can be partly explained by the differ ence in frequencies of the CYP2C9 and VKORC variants (Table 3) .
The frequency of distribution of CYP2C9*1, *2 and *3 in Caucasians are 80, 13 and 7%, respectively. The frequency of CYP2C9*1 alleles is 96.2%, and of CYP2C9*3 is 2-4%, in the Chinese population, while CYP2C9*2 is virtu ally absent in the Asian population [33] . There is a novel CYP2C9 allele found in Chinese subjects, the C65 allele, with a frequency of 5% [34] . As previously mentioned, variant *3 is associated [36] . Different frequencies of VKORC1 allele distri bution among ethnic groups further contributes to interethnic variability. The prevalence of the AA haplotype group, which is more sensitive to warfarin, is only 35-37% in Caucasians, but is much higher, approximately 83-89%, in Asian subjects. The haplotype group B, which requires a larger warfarin dose, has a higher prevalence the in Caucasian population, approximately 58-64%, but is only found in 10-13% of Asian subjects [28, 37] . Among the African-American population, the prevalence of lowdose group A is lower [38] .
Clinical application of the pharmacogenomics-guided dosing algorithm
The most delicate period of warfarin therapy is at the initiation phase, as mentioned earlier.
Traditional clinical practice often employs a fixed loading dose regimen (e.g., 5-10 mg for the first 2-3 days) [39] , and adjustment of dos age by trial and error according to the INR.
Alternatively, dosing algorithms have been developed that incorporate clinical factors, such as age, body weight, sex, concurrent medica tion and indication of warfarin regimen [40, 41] . However, these algorithms are complicated, and their application in clinical practice is limited. Computer programs that incorporate these clini cal variables have also been developed, and stud ies have demonstrated that their usage helps to maintain a more stable INR and reduce compli cation rates in both the induction and mainte nance phase [42, 20] . An example can be found on the Warfarin Dosing website, which generates an initiation dose, as well as maintenance dose, based on clinical information entered [101] .
Since the discovery of CYP2C9 and VKORC1 genes, their association with warfarin dosing requirement has been examined in numer ous studies. Results from selected studies that examined the association of both CYP2C9 and VKORC1 with warfarin dosage are summarized in Table 4 . The largest among them was the study by the International Warfarin Pharmacogenetics Consortium (IWPC), who examined the asso ciation of pharmacogenetics factors and clinical variables with warfarin dosage in a cohort of more than 4000 patients, subsequently deriving a pharmacogenetics model incorporating these variables and validating the model in a separate group of 1000 patients. In this study, the group derived two models from the 'derivation cohort', one incorporating both the genetic information and clinical variables, and the other with only clinical variables. These two models were then www.futuremedicine.com validated in a second cohort, and were compared against a fixeddose regimen of 5 mg of warfarin daily by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose. The results demonstrated that the addition of genetic infor mation provided a dosage prediction that was significantly closer to the actual dosage required than estimates derived from a clinical algorithm or the fixeddose approach (8.5 vs 9.9 vs 13.0%). The accuracy of the pharmacogenetic model in dose prediction was more obvious in patients requiring extreme dosages (i.e., <21 mg/week and >49 mg/week groups), who comprised of 46% of the study population. It also demonstrated that the pharmacogenetic model can reduce the chance of a poor dose estimate (i.e., >20% deviation from actual dosage) by 7.57% when compared with the clinical model. In this study, the number of patients needed to be genotyped in order to obtain an improvement in dosage predic tion was 13.2 for the comparison with the clinical algorithm and 6.0 for the comparison with the fixeddose regimen [43] .
Another prospective multicenter study by the Swedish Warfarin Genetics (WARG) also dem onstrated that by using a multiregression model including variants of VKORC1 (in this study, the group only examine variants of rs9923231), CYP2C9*2 and *3, and clinical information derived from a group of more than 1000 patients, over 50% of the variance in warfarin dose can be explained. This group also validated their model in a separate group of 181 genotyped individu als, and the dosage association was similar to that of the derivation cohort [44] . The WARG group also illustrated several interesting findings. First, carriers of VKORC1 variant alleles reached first therapeutic INR more rapidly and spent more time in the therapeutic range (INR 2-3) . Second, homozygous CYP2C9*3 was associated with unstable anticoagulation, with the least time in the therapeutic range, and was strongly associated with supratherapeutic INR. CYP2C9*3 was also associated with increased bleeding risk, although cases not reaching statistical significance when the whole observation period was taken into account.
However, these data were observational. Whether applying these pharmacogenetics dos ing algorithms to clinical practice translates into better clinical outcomes, such as more rapid attainment of therapeutic INR or a reduction in percentage of outofrange INR, still needs to be clarified. There are only handfuls of random ized trials published that address such issues, and their results remain inconclusive.
The study by Caraco et al. used only CYP2C9 variants as the genetic variants in their dosing algorithm. . This study was able to demonstrate that patients in the genotypeguided group reached therapeutic INR in a shorter period of time, spent more time in the desired INR range, and reached pharmacodynamic steady state ear lier than the control group. However, the dos ing algorithm used in the control group of this study was not derived from a population study, but was based on deduction from previous clini cal data. This study also demonstrated that the incidence of minor bleeding was lower in the gen otypeguided group, although no difference was detected in terms overanticoagulationassociated major bleeding incidence [44] .
The trial by Anderson et al. comprised 200 patients randomized to pharmacogenetics guided or standard dosing. The authors dem onstrated that a pharmacogeneticsguided regi men offers significantly more accurate dosage prediction, and that the improved accuracy was more apparent in predicting the dose require ment in the extreme groups that is, those who require higher or lower than average doses of warfarin, echoing the findings of the IWPC. Pharmacogenomicsguided regimens also sig nificantly decreased the number of required dose adjustments. However, in this study, the authors were not able to demonstrate any sig nificant difference in the percentage in outof range INR between the two arms. Although a significant reduction of the percentage of outofrange INR was demonstrated in the subgroup with multiple variant alleles and wildtype alleles, this did not translate into significant reduction of clinical adverse events. In fact, the serious clinical events in this study were unrelated to outofrange INR [45] .
Another prospective randomized trial by Hillman et al. compared a dosing model based on CYP2C9 genotype with a fixed dose of 5 mg in a small group of 38 patients [46] . Although the primary end point was to measure the feasibil ity of genotypeguided warfarin dosing instead of comparing the clinical outcomes of different dosing regimens, this study reiterates the idea that dose prediction was more accurate with genotype testing. This study was also able to demonstrate that the adverse event occurrence rate was lower in the genotypeguided group. However, the study was underpowered to draw any conclusions from the results. Nevertheless, in this study, the authors were able to demon strate that a genotypeguided dosing model was feasible in clinical practice.
Cost-effectiveness of pharmacogenetic testing
One limitation on the widespread usage of genetic testing in clinical practice is its cost. Commercially available genetic testing kits for both CYP2C9 and VKORC cost approxi mately US$400 [47, 102] , with a turnaround time of approximately 1-6 h [45, 103] . However, this incremental upfront cost may be potentially offset by downstream benefits, such as reduc tion in adverse events and hospitalization, and survival benefits.
Several cost-effectiveness analyses of genetic testing have been performed using the decision tree model. In the study by Eckman et al., genetic testing was not a costeffective strategy in reducing adverse events [47] . By setting the risk reduction at 32% for pharmacogeneticsguided dosing and estimating the cost for genetic test ing at US$400, the cost per qualityadjusted life year (QALY) gained by genetic testing on a male aged 69 years with atrial fibrillation and a congestive heart failure, hypertension, age (>75 years), diabetes, prior stroke (CHADS 2 ) score of two and HEMORR 2 HAGES score of zero was US$172,000 (which is well over the generally accepted societal willingnesstopay of US$50,000 per QALY gained). In this model, the utility of routine genetic testing is unlikely to be cost effective unless a more than 90% reduc tion in adverse events can be achieved, or if the marginal cost is less than US$140. The author also commented that if the model is conducted on an individual with high risk of bleeding (HEMORR 2 HAGE score of 1-2), the marginal costeffective ratio might decrease to below the acceptable US$50,000 per QALY.
Another cost-effectiveness ana lysis published recently showed even higher costs per QALY gained (US$347,059) [48] . . However, in this model, the author used a lower risk reduction (relative percentage reduction in outofrange INRs) of 7%. If a risk reduction of more than 30% is achieved, genetic testing will cost less than US$50,000 per QALY gained, assuming that genetic testing is the only additional cost.
In both of these analyses, the cost-effectiveness would be improved if genetic testing were cheaper or if the genotypeguided dosing algo rithm was used selectively in patients in whom problem in INR control is anticipated.
Future of warfarin genetic testing
In August 2007, the FDA updated the label of warfarin to include the statement that "lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 and VKORC1 enzymes" [104] , and the FDA has sub sequently approved the first commercial genetic test for CYP2C9 and VKORC1 [105] . These ini tiatives have highlighted the importance of genetic influence on warfarin dosage, and have encouraged future research on utilizing genetic information on warfarin dosing. However, the FDA stopped short of recommending univer sal genetic testing for all patients on warfarin therapy. Meanwhile, the recent guidelines from the American College of Chest Physicians (IL, USA) published in June 2008 were against the use of pharmacogeneticsbased initial dosing to individualize warfarin dosing [1] .
The main factor holding back a general recom mendation of genetic screening for patients on warfarin therapy is the lack of strong clinical evidence of its efficacy. Despite the strong cor relation and the good predictive power of genetic information with regard to warfarin dosage, definitive evidence concerning the usefulness of incorporating this information into dosing algo rithms in clinical practice has not been estab lished in recently published randomized trials. It can be postulated that the lack of clinical effi cacy in applying genetic information to warfarin dosing is owing to intraindividual variability, such as diet, concomitant drugs and comorbidity during the warfarinmaintenance phase. Genetic poly morphism being a constant variable might not manifest such strong influence beyond the initiation of the therapy. To further elucidate this issue, a large multicenter Classification of Optimal Anticoagulation through Genetics (COAG) study, as well as a singleblinded and randomized controlled trial, the European Pharmaco genetics of Anticoagulant Therapy (EUPACT) study, are underway to determine if knowledge of genetic information will improve the efficacy and safety of warfarin therapy.
Another concern of applying genetic test ing is its cost. From the results of current cost-effectiveness studies, unless the risk reduc tion of using geneticguided dosing algorithm is more than 60%, geneticguided dosing may not be a costeffective strategy. With the results from the existing pilot clinical trials, the ben efit of geneticguided dosing is far smaller than 50%. Nevertheless, it can be speculated that if genetic testing is performed on individuals with a high risk of bleeding, such as those with a high HEMORR 2 HAGE index, or on populations with a high prevalence of susceptible poly morphisms (such as Asians), the cost-effectiveness model may tilt in favor of genetic testing. Role of warfarin pharmacogenetic testing in clinical practice Review
Conclusion
Better understanding of the individual genetic polymorphisms contributing to the variations in pharmaceutical response of warfarin has enabled us to see beyond the mere biochemical aspects of warfarin dosing by trial and error. The dis covery of genes coding for CYP2C9 and VKOR1 offers us the opportunity to realize the hopes of personalized medicine in which an individual can be prescribed with a specific regimen match ing their particular genetic makeup so that the benefit of treatment can be maximized while minimizing complications. Warfarin, being one of the most widely prescribed drugs and having a narrow therapeutic window, seems to be an ideal candidate for the application of the concept of geneticguided medicine. However, warfarin titration is a tedious process, and the availability of pharmacogenetic testing is not intended to loosen the vigilance of the physician. Rather, it serves to heighten our awareness of the multitudes of factors that affect warfarin dosing, some of which still elude our knowledge, and to alert us of the importance of conscientious clinical monitoring. 
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Executive summary
CYP2C9 genotype is a significant predictor of the average dose of warfarin and the time needed to reach the first out-of-range international normalized ratio
Variant CYP2C9 alleles require a lower maintenance dose, and longer time to reach the therapeutic international normalized ratio range and increase the risk of overanticoagulation. VKORC1 significantly influences warfarin dosage requirement VKORC1 haloptype group A is associated with a lower maintenance dose, and haloptype group B is associated with a higher maintenance dose.
Inter-ethnic variation of warfarin dose can be explained by genetic difference
Compared with Caucasians, Chinese populations have a higher prevalence of CYP2C9*3 and VKORC1 group A haplotypes, and so are more sensitive to warfarin. Pharmacogenomics-guided dosing algorithms provide accurate dosage prediction, but their application in randomized controlled trials yielded inconclusive results
The pharmacogenetics model was more accurate in dose prediction than using clinical variables alone in a multivariate ana lysis. The pharmacogenetics model, however, was only tested in a handful of small-scaled randomized controlled trials, and the evidence of benefit yielded is not strong. Large-scale randomized controlled trials are underway to address this issue.
Genetic testing may not be cost effective
Current cost-effectiveness studies do not support routine pharmacogenetic testing for warfarin dosing. 
